【摘要】 目的:探讨阿立哌唑对老年精神分裂症患者长期治疗的临床疗效和安全性。方法:采用门诊开放性研究,对42例符合CCMD-3精神分裂症诊断标准的老年患者采用阿立哌唑5~20 mg/日治疗,以简明精神病评定量表(BPRS)评价临床有效性,用药物副反应量表(TESS)评价安全性,观察18个月。结果:有36例完成18个月的疗程,占85.71%(36/42),BPRS减分率为73.5%,总有效率为83.33%。不良反应有便秘头晕乏力、失眠、静坐不能等,程度多为轻度和中度,未见严重的不良反应。结论:阿立哌唑能有效缓解老年精神分裂症的精神病性症状,安全性好,适合于门诊老年人的长期治疗。更多还原

【Abstract】 Objective: To investigate the efficacy and safety of Aripiprazole in the treatment of schizophrenia patients with late onset in an 18-month open trial.Methods:Forty-two patients in the study met the diagnostic critter is for schizophrenia described in the CCMD-3.The dosage of Aripiprazole ranged 5~20 mg/day.The brief psychiatric rating scale(BPRS) was used for the efficacy and treatment emergent symptom scale(TESS) for unwanted effects.Results: Aripiprazole demonstrated overall response rate(73.5% decreases in the BPRS total score) and of the patients were rated as improvement.The main side effects of Aripiprazole were mild or middle extent of drowsiness,insomnia,akathisia and dizziness etc.Conclusions: Aripiprazole is safe and effective in the management of psychotic symptoms in old out patients with schizophrenia.更多还原